Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study
Journal of Investigational Allergy and Clinical Immunology · 26.07.2023 · 33 (4) · 271-280
DOI: 10.18176/jiaci.0800 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Investigational Allergy and Clinical Immunology, online erschienen am 27.07.2023. Verfasst von P J Gomes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ora, Inc., Andover, Massachusetts, USA. Hauptthemen laut MEDLINE: Conjunctivitis, Allergic, Anti-Allergic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref).
Abstract (Originalsprache)
Background and objectives: Bilastine is a nonsedating second-generation antihistamine for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. Our study aimed to evaluate the optimal dose, efficacy, and safety of a newly developed once-daily preservative-free ophthalmic formulation of bilastine for allergic conjunctivitis.
Methods
Our phase 2, single-center, double-masked, randomized trial compared the efficacy of 3 doses of a bilastine ophthalmic formulation (0.2%, 0.4%, and 0.6%) with that of vehicle for the treatment of allergic conjunctivitis. The primary efficacy endpoint was the reduction in ocular itching. The Ora-CAC Conjunctival Allergen Challenge model was used to assess ocular and nasal symptoms at the onset of action (15 minutes) and at 8- and 16-hours after treatment. Tolerance and safety were also evaluated.
Results
A total of 121 adults with seasonal and/or perennial ocular allergy were randomized. Bilastine ophthalmic formulations 0.2%, 0.4%, and 0.6% were significantly superior (P>.001) to vehicle for the treatment of ocular itching at 3, 5, and 7 minutes after challenge at onset of action (15 minutes) and at 8 hours after treatment. Bilastine 0.6% was also effective at 16 hours after treatment. Treatment differences for bilastine 0.6% were statistically significant (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ora, Inc., Andover, Massachusetts, USA.
- Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Research, Development, and Innovation, FAES FARMA, Bizkaia, Spain.
Zitieren
APA
Gomes, P. J., Ciolino, J. B., Arranz, P., Hernández, G., & Fernández, N. (2023). Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study. Journal of Investigational Allergy and Clinical Immunology, 33(4), 271-280. https://doi.org/10.18176/jiaci.0800
Vancouver
Gomes PJ, Ciolino JB, Arranz P, Hernández G, Fernández N. Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study. Journal of Investigational Allergy and Clinical Immunology. 2023;33(4):271-280. doi:10.18176/jiaci.0800
BibTeX
@article{Gomes2023,
author = {Gomes, P J and Ciolino, J B and Arranz, P and Hernández, G and Fernández, N},
title = {Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study},
journal = {Journal of Investigational Allergy and Clinical Immunology},
year = {2023},
volume = {33},
number = {4},
pages = {271--280},
doi = {10.18176/jiaci.0800}
}
EUVIMED